J147

Phase 2Small molecule

AAbrexa Pharmaceuticals, Inc.

J147 is one of 13 small molecule programs targeting Acute Ischemic Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Ischemic StrokeRecruiting

Acute Ischemic StrokePhase 2

Recruiting

Competition

Competitive Landscape

14 competitors in Acute Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

4 2

Actemra

CCelltrion

Phase 3

1 3

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

1 4

Rhtnk-Tpa

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Phase 3

1 5

TAK-755

Takeda

Phase 2

1 6

Cerebrolysin

EEver Neuro Pharma GmbH

Phase 2

1 7

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 2

1 8

Anisodine Hydrobromide

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

2 9

J147

AAbrexa Pharmaceuticals, Inc.

Phase 2

1 10

LT3001 Drug Product

LLumosa Therapeutics Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Acute Ischemic Stroke

NCT07430917

Clinical

Trials by Indication[1]

Oral1 trial

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Completed·AAbrexa Pharmaceuticals, Inc.·Phase 1·NCT03838185·64 enrolled

Acute Ischemic Stroke1 trial

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke

Recruiting·AAbrexa Pharmaceuticals, Inc.·Phase 2·NCT07430917·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for J147. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — J147 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for J147. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abrexa Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbrexa Pharmaceuticals, Inc.

J147

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Oral1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News